Lantern Pharma expands predictBBB.ai into real-time small-molecule quantitative model web service

• Lantern Pharma expanded predictBBB.ai into a real-time Large Quantitative Model web service that generates developability analytics for small molecules from a single SMILES string in seconds.
• Platform uses vector representations and molecular fingerprints trained on thousands of characterized compounds, enabling screening of tens of thousands of molecules per day.
• Lantern reported five BBB permeability algorithms ranked among top 12 on Therapeutic Data Commons leaderboard, citing this as a benchmark-validated baseline.
• Company positioned service as a broader small-molecule decision tool beyond CNS, including predictions tied to oral bioavailability and efflux transporter risk such as P-gp.
• Lantern plans to monetize predictBBB.ai via partnerships, licensing, direct access, with subscription-based launch roadmap; enterprise API access remains in development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260429726045) on April 29, 2026, and is solely responsible for the information contained therein.